<Blinded Review: TIME_ANON_0929>
**Composite Score:** 4.4 / 10.0 (Rigor: 1.3/3.5 | Claims: 1.1/2.5 | Biology: 1.1/2.0 | Reproducibility: 0.9/2.0)
**Bias Category:** Technical/Assay
**Verdict:** Major Revision
**Study Modality:** Wet-Lab Primary Experimental
**Technology Maturity:** Mature/Classical
**Epistemic Stage:** Clinical/Observational

OVERALL_SCORE: 4.4/10
VERDICT: CAVEATS
ESTIMATED_DECADE: 1990s

---

### 1. Executive Summary / SUMMARY
This observational clinical pathology study examines the expression of `DCC` (Deleted in Colorectal Carcinoma) and `p53` across 220 formalin-fixed paraffin-embedded ovarian tissue specimens (124 ovarian carcinomas, 41 tumors of low malignant potential [LMP], and 55 benign cystadenomas) by immunohistochemistry (IHC), and across a subset of 46 frozen tissue samples (26 carcinomas, 5 LMP, 8 benign tumors, and 7 normal ovaries) by 35-cycle end-point RT-PCR followed by Southern blot hybridization (`Exon 6–7` and `Exon 17` of `DCC`). The authors report that `DCC` protein immunoreactivity is present in 100% (55/55) of benign cystadenomas, 82.9% (34/41) of LMP tumors, and 56.5% (70/124) of ovarian carcinomas, and correlates inversely with FIGO stage ($P < 0.01$) and histological grade ($P < 0.05$) in serous carcinomas, while showing no correlation with `p53` nuclear accumulation ($P = 0.25$). However, the manuscript suffers from internal numerical contradictions in both Table 1 and Table 2, and relies on non-quantitative 35-cycle end-point RT-PCR without an internal reverse-transcription control.

### STRENGTHS
- **Combined Assessment of Both Benign, Borderline (LMP), and Malignant Ovarian Lesions:** By profiling 55 benign cystadenomas, 41 LMP tumors, and 124 invasive carcinomas across four major histological subtypes (serous, mucinous, endometrioid, clear cell), the IHC cohort provides a broad histological survey of ovarian epithelial neoplasia.
- **Concordance Between Frozen-Tissue RT-PCR/Southern Blot and Paraffin IHC in the 26-Case Subset:** In Table 1, cases with absent (`-`) or reduced (`±`) `DCC` RT-PCR Southern blot signal consistently show negative (`-`) `DCC` immunoreactivity on matched paraffin sections.

### 2. Methodological & Statistical Audit / WEAKNESSES & METHODOLOGICAL AUDIT
- **Internal Arithmetic Contradictions in Table 2 (`p53 expression`) and Results Text:**
  - In Table 2 (`Immunohistochemical analysis of DCC and p53 expressions in ovarian carcinomas`), the row for `Ovarian carcinoma (total)` states that `p53` expression was positive (`+`) in **`57` (`46.0%`)** and negative (`-`) in **`67` (`54.0%`)** of the `124` cases ($57 + 67 = 124$).
  - Immediately below this row, `Subtypes` partitions the exact same `124` cases into `Serous (n = 51)` and `Non-serous (n = 73)` ($51 + 73 = 124$). Yet for `p53 expression`, `Serous (+)` is **`36` (`70.6%`)** and `Non-serous (+)` is **`17` (`23.3%`)**. Summing the subtypes gives $36 + 17 = \mathbf{53}$ positive cases (and $15 + 56 = \mathbf{71}$ negative cases), which directly contradicts the total of **57 positive and 67 negative cases** reported in the line above (and in Table 3, where $29 + 28 = 57$)!
  - Similarly, in the Results text (`Detection of DCC mRNA Expression by RT-PCR`), the authors write: *"DCC mRNA expression decreased or was lost in ten (34.5%) of 26 carcinomas (Fig. 1 and Table 1)."* First, $10 / 26 = \mathbf{38.5\%}$, not `34.5%` ($10 / 29 = 34.5\%$, suggesting a denominator mix-up). Second, inspecting Table 1 (`C1` through `C27`, with `C9` omitted = 26 cases), there are actually **11 cases** with `-` or `±` in Exon 6/7 or Exon 17 (`C3, C4, C5, C10, C15, C19, C20, C22, C24, C26, C27`), and 10 cases with `-` in the `IHC` column (`C3, C4, C5, C10, C15, C19, C20, C24, C26, C27`, whereas `C22` has `±` in Exon 17 RT-PCR but `+` in IHC)!
- **Flawed Semi-Quantitative Densitometry on 35-Cycle End-Point RT-PCR and Uncoupled `β-actin` Genomic DNA Control:**
  - The authors amplify `DCC` cDNA for **35 cycles** of PCR (`94°C 1 min, 56°C 2 min, 72°C 2 min`) and classify tumors as having `"reduced expression (±; 10 to 50% of normal intensity)"` via densitometry of Southern blots of the 35-cycle PCR products. At 35 cycles of PCR, amplification is deep in the plateau phase, where end-point band intensity does not linearly reflect starting mRNA copy number.
  - Worse still, in Materials and Methods (`RT-PCR and Southern Blot Hybridization`), the `β-actin` control was amplified from *"0.1 μg of genomic DNA"* rather than from the reverse-transcribed cDNA (`1 μg total RNA`)! Amplifying `β-actin` from genomic DNA cannot control for RNA integrity, RNA input, or reverse transcription efficiency in the RT-PCR reaction.
- **No Multiple-Testing Adjustment or Multivariable Modeling:**
  - Multiple $\chi^2$ and Fisher's exact tests are performed across histological subtypes, stages, grades, and lymph node status in small subgroups (e.g., only $n=5$ Stage I/II serous carcinomas vs. $n=46$ Stage III/IV serous carcinomas in Table 2) without multivariable adjustment for stage/grade collinearity.

### 3. Biological / Experimental Grounding & Claim Proportionality
- **Claim 1:** *`DCC` immunoreactivity is progressively lost from benign ovarian cystadenomas (100% positive) to LMP tumors (82.9% positive) and invasive ovarian carcinomas (56.5% positive).* `[Moderately Supported]` — Supported by the 220-case IHC series, though scoring thresholds (`<10%` vs. `>70%` positive cells, with no intermediate `10–70%` cases encountered across 220 tumors!) are unusually binary.
- **Claim 2:** *`DCC` mRNA expression was lost or quantitatively reduced in 34.5% (10/26) of ovarian carcinomas by RT-PCR Southern blot densitometry.* `[Methodologically Flawed]` — 35-cycle end-point PCR is saturated, the `β-actin` control was run on genomic DNA rather than cDNA, $10/26$ is $38.5\%$ (not $34.5\%$), and Table 1 actually shows 11 cases with `-` or `±` in `DCC` RT-PCR.
- **Claim 3:** *Alterations of `DCC` and `p53` occur independently in ovarian carcinogenesis ($P = 0.25$).* `[Moderately Supported]` — Supported by the contingency table (Table 3), subject to the unresolved 4-case arithmetic discrepancy in `p53` counts in Table 2.

### 4. Reproducibility & Data Completeness
- **Primer Sequences & Antibodies:** PCR primer sequences (`O1/O2`, `P1/P2`), internal oligo probes (`O3`, `P3`), and antibody clones (`G97-449` for `DCC`; `DO-1` for `p53`) are fully specified. Patient-level data for the 26 frozen carcinoma cases (`C1–C27`, omitting `C9`) are provided in Table 1.
</Blinded Review: TIME_ANON_0929>
